The Potential Protective Effect of Using Muscle Relaxants During Electroporation Ablation (PFA)
RecruitingNot applicableNCT06707532
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
The study aims to improve the safety of the electroporation ablation (PFA) procedure by using muscle relaxants to reduce skeletal muscle damage during the procedure. It will also assess myocardial damage to improve the procedure's quality and speed up recovery after the procedure.
Study details
- Official title
- The Use of Muscle Relaxants During Electroporation Ablation (PFA) as a Potential Protective Factor Against Damage to Transverse Striated Muscle Tissue and the Heart
- Conditions
- Kidney Failure, Acute
- Myopathy
- Drugs
- Heart Arrhythmia
- Succinylcholine Sensitivity
- Muscle Relaxation
- General Anesthetic Drug Adverse Reaction
- Projection
- Interventions
- Drug: Propofol
- Drug: Rocuronium
- Sponsor
- 4th Military Clinical Hospital with Polyclinic, Poland
- Start date
- 2024-08-01
- Primary completion
- 2025-12-01
- Sex
- All
- Age range
- from 18 Years to 90 Years
- Results posted
- No results posted in this snapshot
- Countries
- Poland
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Patients with requirement for PFA ablation for cardiac indications and ability to provide informed consent for study participation Exclusion Criteria: * Patients with allergies to the general anaesthetics used, genetic diseases of the neuromuscular plateau - e.g. Duchenne dystrophy, myasthenia gravis - and patients who do not gived informed consent to participate in the study will be excluded from the study.
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT06707532